Beschreibung:
<jats:title>Abstract</jats:title>
<jats:p>Objective: To identify disparities in care and survival in ovarian cancer patients treated at a high volume academic center.</jats:p>
<jats:p>Methods: A review of epithelial ovarian cancer cases treated between 01/01/97 and 12/31/07 was conducted. Demographic, clinico-pathologic, insurance carrier, and treatment data were collected. Insurance carrier was categorized into three groups: Commercial, Medicare, and Medicaid. ANOVA or Kruskal-Wallis tests were utilized for continuous variables and chi-square or Fisher’s exact tests for categorical variables. Univariable Cox proportional hazards model was used to estimate hazard ratios for demographic and pathologic variables identified in association with survival. Multivariable Cox regression models were fitted with insurance status as the main exposure. Kaplan-Meier survival curves were generated for race, income, and insurance and compared utilizing log-rank tests.</jats:p>
<jats:p>Results: 279 epithelial ovarian cancer cases were identified out of 460 total ovarian cancer cases. 199 (71%) were White and 80 (29%) were non-White. 159 (57%) had commercial insurance followed by 71 (25%) and 49 (18%) with Medicaid and Medicare, respectively. 166 (60%) of the study group had less than $45,000 as an annual median income. 219 (78%) patients underwent primary debulking surgery. Of the three insurance categories, women with commercial insurance had a survival advantage (p= 0.002). Medicaid was associated with worse survival after adjusting for grade, stage, residual disease, and chemotherapy (p= 0.04). Survival rates in advanced stage disease were similar across the 3 insurance carriers.</jats:p>
<jats:p>Conclusions: Ovarian cancer survival disparities persist at a high volume center but are largely eliminated in advanced stage.</jats:p>
<jats:p>Citation Format: Hayley Hunt, MD, Noah Rodriguez, MD, Keiji Oda, MPH, Robert J. Wagner, MD, Ron E. Swensen, MD. Ovarian cancer disparities in a high volume academic medical center [abstract]. In: Proceedings of the 10th Biennial Ovarian Cancer Research Symposium; Sep 8-9, 2014; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(16 Suppl):Abstract nr POSTER-CTRL-1209.</jats:p>